Residency · Residency · Medicine Pediatrics

Obstructive Sleep Apnea in Children and Adults

Overview

Obstructive sleep apnea (OSA) is characterized by repetitive upper airway collapse during sleep, causing intermittent hypoxia and sleep fragmentation. The pathophysiology, diagnostic criteria, and management differ substantially between children and adults. Adenotonsillar hypertrophy drives most pediatric OSA, while obesity and upper airway anatomy predominate in adults. The Med-Peds physician must recognize the distinct presentations and cardiovascular consequences across ages.

Epidemiology

Pediatric prevalence: 1-5% of children; peak age 2-8 years (adenotonsillar peak) Adult prevalence: 10-30% (increasing with obesity epidemic); higher in men, postmenopausal women, and older adults. Pediatric OSA is underdiagnosed -- many children present with behavioral problems rather than classic sleepiness. Adult OSA is also underdiagnosed -- estimated 80% of moderate-severe OSA in adults is undiagnosed.

Pathophysiology

Pediatric OSA

Adenotonsillar hypertrophy: most common cause; adenoids and tonsils grow relative to airway size, peaking at ages 2-8. Craniofacial abnormalities: Down syndrome (midface hypoplasia, macroglossia, hypotonia), Pierre Robin sequence (micrognathia), Treacher Collins, achondroplasia. Neuromuscular disorders: hypotonia (cerebral palsy, muscular dystrophy) reduces pharyngeal tone. Obesity-related OSA: increasingly common; adipose deposition narrows pharyngeal airway; may not resolve with adenotonsillectomy alone. Laryngomalacia: in infants. Allergic rhinitis and nasal congestion: contribute to mouth breathing and airway obstruction.

Adult OSA

Obesity: most important risk factor; BMI >30 increases risk 3-fold; neck circumference >17 inches (men) or >16 inches (women) correlates with severity. Upper airway anatomy: retrognathia, macroglossia, large uvula, low-lying soft palate (Mallampati III-IV) Loss of neuromuscular tone: age-related decline in pharyngeal dilator muscle activity. Fluid redistribution: nocturnal rostral fluid shift in CHF, ESRD, and sedentary patients. Central obesity + metabolic syndrome: bidirectional relationship.

Clinical Presentation

Pediatric OSA

Nighttime: snoring (most common symptom), witnessed apneas, mouth breathing, restless sleep, enuresis, diaphoresis, paradoxical breathing, unusual sleep positions (hyperextended neck) Daytime: morning headaches, behavioral problems (ADHD-like presentation), poor school performance, irritability, difficulty concentrating. NOTE: unlike adults, children with OSA often do NOT present with daytime sleepiness; behavioral changes predominate. Growth failure: in severe cases (increased metabolic demand, decreased growth hormone secretion during fragmented sleep) Examination findings: tonsillar hypertrophy (3+ or 4+ Brodsky scale), adenoid facies (long face, open mouth, narrow palate), obesity.

Adult OSA

Nighttime: loud snoring, witnessed apneas (bed partner report), gasping/choking during sleep, nocturia, insomnia. Daytime: excessive daytime sleepiness (EDS -- cardinal symptom), morning headaches, fatigue, unrefreshing sleep, cognitive impairment, mood changes, sexual dysfunction. Screening tools: STOP-BANG questionnaire (Snoring, Tiredness, Observed apneas, Pressure [HTN], BMI >35, Age >50, Neck circumference >40 cm, Gender male) -- score >=3 indicates intermediate risk, >=5 high risk. Epworth Sleepiness Scale (ESS): score >10 suggests excessive daytime sleepiness.

Diagnosis

Polysomnography (PSG) -- Gold Standard for Both

Pediatric PSG criteria (AASM): Obstructive apnea: >=2 missed breaths with continued respiratory effort. AHI (apnea-hypopnea index) >=1 event/hour is abnormal in children. Also assess: nadir SpO2, sleep architecture disruption, CO2 levels (end-tidal or transcutaneous) Adult PSG criteria (AASM): AHI >=5 with symptoms or AHI >=15 regardless of symptoms. RDI (respiratory disturbance index) includes RERAs (respiratory effort-related arousals)

Home Sleep Apnea Testing (HSAT)

Adults: acceptable for uncomplicated suspected moderate-severe OSA in adults without significant comorbidities; not for central sleep apnea, hypoventilation syndromes, or complex cases. Children: NOT recommended; in-lab PSG is the standard; children require CO2 monitoring and pediatric-specific scoring.

Screening Questionnaires

Pediatric Sleep Questionnaire (PSQ): validated screening tool for children. STOP-BANG: adults; most widely used. Questionnaires are screening tools only -- they do not replace PSG for diagnosis.

Consequences of Untreated OSA

Pediatric

Neurocognitive: learning difficulties, poor academic performance, behavioral problems, ADHD misdiagnosis. Cardiovascular: pulmonary hypertension (rare but serious), systemic hypertension, right ventricular dysfunction. Growth: failure to thrive, impaired growth hormone secretion. Quality of life: enuresis, mood disturbance, decreased daytime functioning. Metabolic: insulin resistance, dyslipidemia (emerging data)

Adult

Cardiovascular: systemic hypertension (OSA is the leading identifiable cause of resistant HTN), atrial fibrillation, coronary artery disease, stroke, heart failure, pulmonary hypertension. Metabolic: insulin resistance, type 2 diabetes, metabolic syndrome. Neurocognitive: impaired concentration, memory deficits, depression, motor vehicle accidents (2-3x increased risk) Mortality: untreated severe OSA increases all-cause and cardiovascular mortality.

Management

Pediatric OSA

Adenotonsillectomy (T&A)

First-line treatment for pediatric OSA with adenotonsillar hypertrophy. Curative in 75-80% of non-obese children with OSA. CHAT trial (Childhood Adenotonsillectomy Trial): T&A improved behavior, quality of life, and PSG findings compared to watchful waiting, but did not significantly improve attention or executive function on neuropsychological testing. Post-T&A PSG recommended 6-8 weeks after surgery in high-risk patients (severe OSA, obesity, craniofacial anomalies, Down syndrome) to assess for residual OSA. Complications: hemorrhage (3-5%), dehydration, post-obstructive pulmonary edema (rare, in severe OSA)

CPAP/BiPAP

For residual OSA after T&A, or when T&A is not indicated/contraindicated. Adherence is the major challenge in children; behavioral desensitization strategies are essential. Mask fitting and interface selection require pediatric expertise. Minimum age: can be used in infants with appropriate interfaces.

Other Interventions

Intranasal corticosteroids + montelukast: mild residual OSA after T&A; anti-inflammatory effect on lymphoid tissue. Weight management: essential for obese children with OSA (OSA may persist or recur after T&A in obese children) Orthodontic interventions: rapid maxillary expansion for narrow palate. Myofunctional therapy: oropharyngeal exercises; emerging evidence. Supplemental oxygen: temporizing for severe hypoxemia while awaiting definitive treatment.

Adult OSA

PAP Therapy (CPAP/Auto-PAP)

First-line treatment for moderate-severe OSA in adults. Mechanism: pneumatic splint maintaining airway patency. Auto-titrating PAP (APAP): adjusts pressure automatically; acceptable alternative to in-lab CPAP titration for most patients. Adherence: >=4 hours/night on >=70% of nights is the CMS definition of compliance; real-world adherence is 50-60%. Strategies to improve adherence: proper mask fitting, heated humidification, ramp function, behavioral support, telemedicine monitoring, treating nasal congestion.

Oral Appliances (Mandibular Advancement Devices)

Alternative to CPAP for mild-moderate OSA or CPAP intolerance; Custom-fitted by dental sleep medicine specialist; Less effective than CPAP but better adherence may compensate; Not recommended for severe OSA as primary therapy.

Surgical Options (Adults)

Uvulopalatopharyngoplasty (UPPP): variable success (30-50%); largely replaced by more targeted approaches. Hypoglossal nerve stimulation (Inspire device): for moderate-severe OSA with CPAP intolerance; AHI 15-65, BMI <35, no concentric collapse on DISE (drug-induced sleep endoscopy) Maxillomandibular advancement (MMA): highly effective but invasive. Bariatric surgery: for morbidly obese patients; significant improvement but rarely curative.

Weight Management

10% weight loss can reduce AHI by 26-50%. GLP-1 receptor agonists (semaglutide, tirzepatide): showing significant AHI reduction in obese patients with OSA (SURMOUNT-OSA trial) May allow CPAP pressure reduction or discontinuation in some patients.

Positional Therapy

Supine-predominant OSA: positional device to maintain lateral sleep position. Limited to patients with clear positional component.

<image>A comparison of OSA pathophysiology in children versus adults. The pediatric panel shows a sagittal cross-section of a child's upper airway with enlarged adenoids and tonsils narrowing the nasopharynx and oropharynx, with arrows indicating obstruction points. The adult panel shows a sagittal cross-section with retrognathia, elongated soft palate, adipose tissue deposition in the pharyngeal walls, and macroglossia. Below each panel, a PSG tracing shows the characteristic obstructive apnea pattern with paradoxical respiratory effort, desaturation, and arousal, with age-specific AHI thresholds (pediatric: abnormal at 1/hr; adult: abnormal at 5/hr).</image>

<image>A treatment algorithm for pediatric OSA showing the decision pathway from PSG diagnosis through management options. Starting with AHI severity classification, the flowchart branches to adenotonsillectomy as first-line for most children, with post-T&A PSG assessment. Residual OSA branches to CPAP, intranasal steroids plus montelukast (for mild residual), weight management (for obese children), and orthodontic interventions. Special populations (Down syndrome, craniofacial anomalies, neuromuscular disease) are highlighted with modified management pathways.</image>

<image>An infographic showing the cardiovascular and neurocognitive consequences of untreated OSA across the lifespan. A central timeline from childhood to old age shows the progressive organ damage: in childhood, behavioral problems, ADHD-like symptoms, growth failure, and pulmonary hypertension; in young adulthood, hypertension and metabolic syndrome; in middle and older adulthood, atrial fibrillation, coronary artery disease, stroke, heart failure, and motor vehicle accidents. Risk reduction with treatment is annotated at each stage.</image>

Clinical Pearls

Children with OSA typically present with behavioral problems and ADHD-like symptoms, NOT daytime sleepiness -- this is a fundamental difference from adult OSA. An AHI >=1 is abnormal in children (vs. >=5 in adults) -- different diagnostic thresholds apply. Adenotonsillectomy is first-line for pediatric OSA with adenotonsillar hypertrophy and is curative in approximately 75-80% of non-obese children. Obese children with OSA may not be cured by adenotonsillectomy alone -- post-operative PSG and ongoing weight management are essential. STOP-BANG >=3 should prompt evaluation for OSA in adults; a score >=5 is high-risk. CPAP adherence is the Achilles heel of adult OSA management -- behavioral support, proper mask fitting, and telemedicine monitoring improve outcomes. OSA is the leading identifiable cause of resistant hypertension in adults -- always screen for OSA in patients with uncontrolled HTN on 3+ medications. Home sleep testing is acceptable for uncomplicated adult OSA but is NOT appropriate for children -- in-lab PSG with CO2 monitoring is the pediatric standard. GLP-1 agonists are emerging as a game-changer for obesity-related OSA in adults.

References

• Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome (AAP Clinical Practice Guideline). Pediatrics. 2012;130(3):e714-e755.
• Marcus CL, Moore RH, Rosen CL, et al. A randomized trial of adenotonsillectomy for childhood sleep apnea (CHAT trial). N Engl J Med. 2013;368(25):2366-2376.
• Patil SP, Ayappa IA, Caples SM, et al. Treatment of adult obstructive sleep apnea with positive airway pressure: an AASM clinical practice guideline. J Clin Sleep Med. 2019;15(2):335-343.
• Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an AASM clinical practice guideline. J Clin Sleep Med. 2017;13(3):479-504.
• Malhotra A, Watanabe M, Engel S, et al. Tirzepatide for treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(14):1288-1300.

Read this lecture as Markdown